EXPRESS MAIL NO.: EV 346 809 883 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Vered HORNIK et al.

Confirmation No.

Application No.: 09/644,456

Group Art Unit: 1631

Filing Date: August 24, 2000

Examiner: Michael Borin

For: CONFORMATIONALLY CONSTRAINED

Attorney Docket No.: 87534-3100

BACKBONE CYCLIED INTERLEUKIN-6

ANTAGONISTS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In response the Examiner's comments, enclosed are copies of fifty seven (57) references for the Examiner's review and consideration. These references are listed on PTO form 1449 enclosed herein. It is respectfully requested that these references be made of record in this application by the Examiner's completion and return of the PTO Form 1449.

The fee which is believed to be due for this submission is \$180. Please charge all required fees to Winston & Strawn Deposit Account No. 501-814.

Respectfully submitted,

Date: 10 - 14 - 03

Allan A. Fanucci

(Reg. No. 30,256)

WINSTON & STRAWN LLP **CUSTOMER NO. 28765**

(212) 294-3311

Enclosure

10/20/2003 JBALINAN 00000141 501814 09644456

01 FC:1806

180.00 DA

ATTY. DOCKET NO.:

APPLICATION NO.:

87534-3100

O9/644,456

APPLICANT:

Vered HORNIK et al.

Filing date:

GROUP:

AUGUST 24, 2000

APPLICATION NO.:

09/644,456

APPLICANT:

Vered HORNIK et al.

rī 1 4 2003	22	(Use several sheets if	necessary)	Vered HORNIK et al.	Vered HORNIK et al. FILING DATE: GROUP:					
7 / 4 -	(Use several sheets if necessary)			August 24, 2000						
	Est. S	-		PATENT DOCUMENTS						
BAD ER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING APPROI	DATE IF PRIATE		
_	AA	3,988,304	10/1976	Garsky	260	78A				
	AB	4,011,182	03/1977	Sarantakis	260	8				
	AC	4,054,558	10/1977	Garsky	260	112.5S				
	AD	4,187,217	02/1980	Chipens et al.	260	112.5R				
	AE	4,235,886	11/1980	Freidinger et al.	424	177				
	AF	4,310,518	01/1982	Freidinger et al.	424	177				
	AG	5,364,851	11/1994	Joran	530	345				
	АН	5,371,070	12/1994	Koerber et al.	514	9				
	AI	5,770,687	01/1998	Hornik et al.	530	311				
	AJ	5,874,529	02/1999	Gilon et al.	530	317				
	AK	5,883,293	06/1999	Gilon et al.	562	455				
	AL	6,051,554	04/2000	Hornik et al.	514	11				
	1 1		FOREI	GN PATENT DOCUMENTS		1				
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSL	NO		
	AM	2,304,352	10/1976	France						
	AN	2,411,828	07/1979	France						
	AO	0 031 303	07/1981	EPO						
	AP	WO 89/01781	03/1989	PCT						
	AQ	0 334 244 A2	09/1989	EPO						
	AR	0 336 779 A2	10/1989	ЕРО						
	AS	0 370 453 B1	05/1990	ЕРО						
	AT	0 395 417	10/1990	ЕРО						
	AU	0 336 779 A3	08/1991	ЕРО						
	ΑV	WO 92/00091	01/1992	PCT						
	AW	41 19 544 C1	10/1992	Germany						
	AX	WO 92/22566	12/1992	PCT						
			·							

			<u></u>			······································				
r 5003	AY	WO 93/01206	01/1993	PCT						
4 St.	AZ	0 564 739 A2	10/1993	ЕРО						
MARI	ВА	WO 94/11393	05/1994	PCT						
	вв	WO 95/01800	01/1995	PCT						
	вс	0 564 739 A3	04/1995	EPO						
<u>.</u>	<u>. </u>	OTHER R	EFERENCES (Including Author, Title, Date, Pertinent Page	es, Etc.)					
	BD	Bell et al., 1993, "Molec	ular biology of s	omatostatin receptors," TINS, Vol. 16, No. 1	1, 34-38.					
	BE	Brazeau et al, 1973, "Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreative Pituitary Growth Hormone", SCIENCE, Vol. 179, pp. 77-79								
	BF	Buscail et al., 1995, "Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms," Proc. Natl. Acad. Sci. USA 92: 1580-1584.								
	BG	Byk et al., 1992, "Building units for N-backbone cyclic peptides. 1. Synthesis of protected N-(ω-aminoalkylene)amino acids and their incorporation into dipeptide units", <i>J. Org. Chem.</i> 57:5687-5692								
	вн	Charpentier et al., 1989, "Synthesis and binding affinities of cyclic and related linear analogues of CCK ₈ selective for central receptors," J. Med. Chem., pp. 1184-1190.								
	BI	Giannis et al., 1993, "Peptidomimetics for receptor ligands - discovery, development, and medical perspectives," Angew. Chem. Int. Ed. Engl. 32: 1244-1267.								
	BJ	Gilon et al., 1991, "Backbone Cyclization: A New Method for Conferring Conformational Constraint on Peptides", Biopolymers 31:745-750								
	вк	Gilon et al., 1992, "SAR studies of cycloseptide: effects of cyclization and charge at position 6," Chem. Biol. Proc. Am. Pept. Symp 1th. pp. 476-477.								
	BL	Greiner et al., 1994, "Synthesis of New Backbone-Cyclized Bradykinin Analogs", <i>Proc. Eur. Pept. Symp.</i> , 23rd, Meeting Dat 1994, 289-290								
	ВМ	Hruby et al., 1990, "Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations," Biochem. J. 268: 249-262.								
	BN	Klein, et al., 1995, "Interleukin-6 in Human Multiple Myeloma," Blood, Vol. 85, No. 4, pp. 863-872.								
	во	Krstenansky et al., 1994, "Cyclic hexapeptide antagonists of the bradykinin B ₂ receptor: Receptor binding and solution backbone conformation", Letters in Peptide Science 1:229-234								
	ВP	Lamberts, 1988, "The role of Somastatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors," Endocrine Reviews Vol. 9, No. 4, pp. 417-436.								
	ВQ	Lamberts et al., 1990, "Somastatin-receptor imaging in the localization of endocrine tumors," New England J. Med. 323: 1249.								
	BR	Lymangrover et al., 1993, "Varying the duration of A23187 administration alters its effect on adrenal steroidogenesis," Life sciences 34:371-377.								
	BS	Mosberg et al., 1983, "Bis-penicillamine enkephalins possess highly improved specificity toward δ opioid receptors," Biochemistry 80:5871-5874.								
	ВТ	Plotsky et al., 1985, "Patterns of growth hormone-releasing factor and somatostatin secretion into the hypophysial-portal circulation of the rat," Science 230:461-463.								
	BU	Raynor et al., 1993, "Clo	ned somatostati	n receptors: identification of subtype-selective	ve pentides and de	emonstration of	high			

IPE		affinity binding of linear peptides," Mol. pharmacol. 43:838-844.					
1 4 2003	BV	Reisine et al., 1995, "Molecular biology of somatostatin receptors," Endocrine reviews 16, 427-442.					
	BW	Reubi et al., 1995, "Multiple actions of somatostatin in neoplastic disease," TIPS 16: 110-115.					
DEMARK	вх	Rizo et al., 1992, "Constrained peptides: Models of bioactive peptides and protein substructures," Annu. Rev. Biochem. 61:387-418.					
	BY	Rodriguez et al. 1990, "Synthesis of cyclic analogues of cholecystokinin highly selective for central receptors," Int. J. Peptic Protein Res. 35:441-451.					
	BZ	Rudinger, 1976, "Characteristics of the Amino Acids as components of a peptide hormone sequence," Peptide Hormones, Ed J.A. Parsons, University Park Press, Baltimore, pp.1-7					
	CA	Schumann et al., 1996, Database Caplus, DN: 130:14228. Pept. 1996, Proc. Eur. Pept. Symp., 24th (1998). Meeting Date 1996, 797-798. Editors: Ramage, Robert; Epton, Roger. Publisher: Mayflower Scientific, Kingswinford, UK.					
	СВ	Steranka et al., 1988, "Bradykinin as a pain mediator: receptors are localized to sensory neurons, and antagonists have analgesic actions," Proc. Natl. Acad. Sci. USA 85:3245-3249.					
	СС	Verber et al., 1984, "A super active cyclic hexapeptide analog of somatostatin," Life sciences 34:1371-1378.					
	CD	Verber et al., 1985, "The design of metabolically-stable peptide analogs," TINS, pp. 392-396.					
	CE	Zuckerman, 1993, "The chemical synthesis of peptidomimetic libraries," Current Opinion in Structure Biol., 3: 580-584.					
		EXAMINER DATE CONSIDERED	· · · · · · · · · · · · · · · · · · ·				
*EXAM	IINER:	R: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through in conformance and not considered. Include copy of this form with next communication to applicant.	citation if not				